Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438427 | 1.00 | KIF11 (0.73) | KIF11ALDH1A1SMN1; SMN2KDM1AKDM4E | |
| SCHEMBL18230875 | 0.84 | KIF11 (0.54) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL67628 | 0.83 | KIF11 (0.58) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL10299815 | 0.83 | KIF11 (0.58) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL472408 | 0.83 | KIF11 (0.56) | KIF11ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL20740835 | 0.83 | KIF11 (0.56) | KIF11KDM1ACYP11B1CYP11B2 | |
| SCHEMBL3034920 | 0.82 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL30874807 | 0.82 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL16846737 | 0.82 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 | |
| SCHEMBL14636222 | 0.81 | KIF11 (0.51) | KIF11ALDH1A1SMN1; SMN2KDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| CN-119569635-A | Biaryl ring inhibitors targeting c-Myc proteins | 上海深势唯思科技有限责任公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| WO-2001058893-A2 | INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001036422-A1 | TRICYCLIC DIHYDROPYRIMIDINE POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001034591-A2 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6162918-A | Xanthene and acridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-5969139-A | INHIBITORS OF HERPES SIMPLEX VIRUS THYMIDINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0823426-A1 | Xanthene and acridine derivatives and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | KIF11 4205/4885ALDH1A1 1031/4885SMN1; SMN2 3896/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | KIF11 3898/4885ALDH1A1 3306/4885SMN1; SMN2 84/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | KIF11 4205/4885ALDH1A1 1031/4885SMN1; SMN2 3896/4885 |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | CES1, NCEH1, NR1H2 | KIF11 3494/4885ALDH1A1 778/4885SMN1; SMN2 3177/4885 |
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | KIF11 2655/4885ALDH1A1 1344/4885SMN1; SMN2 2455/4885 |
| US-12448371-B2 | Inhibitor compounds | SERPINB1, MMP1, SSB | KIF11 4192/4885ALDH1A1 1616/4885SMN1; SMN2 863/4885 |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | KIF11 4625/4885ALDH1A1 4861/4885SMN1; SMN2 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.